Clinical features of CMML are quite heterogeneous. More than 90% of CMML patients have one or more gene mutations; however, no disease-specific gene mutation has been identified. Mutations in TET2, SRSF2, ASXL1, and RAS genes are frequently detected and ASXL1 mutations negatively affect the disease outcome. Moreover, it has been clarified that the clonal architecture of CMML is characterized by linear accumulation of mutations [3] . Recently, international consortium perspectives in diagnostic recommendations and response criteria were reported, and clinical reports on CMML, including a new diagnostic method, molecularly integrated CMML-specific prognostic models, and therapeutic trials, are increasing.
Myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are defined as stem cell disorders caused by various gene abnormalities. Recent analysis using next-generation sequencing (NSG) has provided great advances in identifying relationships between gene mutations and clinical phenotypes. Gene mutations affecting RNA splicing machinery, DNA methylation, histone modifications, transcription factors, signal transduction proteins, and components of the cohesion complex participate in the pathogenesis and progression of these myeloid neoplasms [1] .
JAK2, calreticulin (CALR), and MPL mutations which are frequently detected in patients with classical MPN have been shown to constitutively active cytokine receptors. JAK2 V617F activates erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL, whereas the functions of CALR mutants and MPL mutants are MPL activation only. Recently, the molecular mechanisms by which CALR mutant promotes the development of MPN were clarified [2] . Therefore, the development of novel therapeutic targets for MPN with CALR mutant is expected.
MDS/MPN is characterized by overlapped features of bone-marrow failure in MDS and myeloproliferation in MPN. Although much was unknown to the molecular abnormalities of MDS/MPN, gene analysis using NSG is beginning to uncover the gene mutations defining clinical characteristics. According to 2016 World Health [5] . Therefore, the development of new molecular target therapies to spliceosome is expected for MDS/MPN patients with spliceosome gene mutations. This review series in the Progress in Hematology highlight MPN and MDS/MPN based on molecular pathogenesis and clinical aspects. I hope that the reviews by four expert authors will be of great interest to the readers of the International of Hematology.
